- At "AMWC SEA 2024," one of the world's top three aesthetic medicine congresses, the Nabota booth ...
MILAN, Oct. 10, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-jae L...
SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOsChang-Jae Lee and...
SEOUL, South Korea, May 14, 2024 /PRNewswire/ -- CGBio, a leading medical device company, announced...
SEOUL, South Korea, Nov. 28, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is pleased to announce th...
'Fexuprazan,' Novel drug for Gastroesophageal Reflux Disease, starts its release inthe Philippines....
– Daewoong Pharmaceutical, "Expecting the smooth approval with the successful phase 3 clinical tria...
SEOUL, South Korea, July 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical obtained approval for a S...
* Elucidated molecular mechanism behind safety and efficacy of Bersiporocin * Bersiporocin is cu...
- New investigational data evaluating Fexuprazan in a Korean clinical trial program for healing er...
- Exclusive rights for the development and commercialization of DWP213388 in the global market to V...
SEOUL, South Korea, April 24, 2023 /PRNewswire/ -- The research results of Daewoong Pharmaceutical'...
- 'Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to tar...
* Submitted an NDA to Indonesia, Philippines and Thailand * Signed the export contract in Brazil...
- Hitting a record high sale with business profits of KRW 106 billion and net profits ofKRW 80.1 bi...
- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks -...
* Daewoong Pharmaceutical to receive up to $76M upfront and development milestone payment plus a...
"Expected to change GERD drug market landscape" * Application for product approval of Fexuclue, ...
* Delivers new drug for two consecutive years by obtaining product license on "Envlo", Korea's 36...
* Nabota exports grew significantly, achieving a 93.3% growth YOY, and overall revenue topsKRW 40...
